Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

24.0K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.0K
Genome Copying Errors02:46

Genome Copying Errors

4.3K
DNA replication is a well-evolved process that copies millions of base pairs with high fidelity during each cell division. Occasionally a wrong base or a long stretch of wrong bases may get added to the daughter strands. If the errors are left unchecked, cells might accumulate several mutations that might endanger their  survival. Therefore, the copying errors are checked and repaired at three levels.
4.3K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

234
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
234
Biosynthesis of Nucleic Acids01:28

Biosynthesis of Nucleic Acids

158
Nucleic acid biosynthesis is a fundamental biochemical process that produces the purine and pyrimidine nucleotides essential for DNA and RNA synthesis. This pathway maintains a balanced nucleotide pool, preventing imbalances that could jeopardize genetic integrity and cellular function. Given the crucial role of nucleotides, their synthesis is tightly regulated to ensure proper cellular homeostasis.Purine BiosynthesisThe biosynthesis of purine nucleotides begins with ribose-5-phosphate, a...
158
Translation01:31

Translation

15.3K
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Proteins are...
15.3K
Nonsense-mediated mRNA Decay02:27

Nonsense-mediated mRNA Decay

10.8K
The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
10.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Leveraging the Aggregated Protein Dye YAT2150 for Malaria Chemotherapy.

Pharmaceutics·2024
Same author

Insights into the Pharmacogenetics of Tacrolimus Pharmacokinetics and Pharmacodynamics.

Pharmaceutics·2022
Same author

OncomiRs miR-106a and miR-17 negatively regulate the nucleoside-derived drug transporter hCNT1.

Cellular and molecular life sciences : CMLS·2021
Same author

The Physicochemical, Biopharmaceutical, and In Vitro Efficacy Properties of Freeze-Dried Dexamethasone-Loaded Lipomers.

Pharmaceutics·2021
Same author

Dexamethasone-Loaded Lipomers: Development, Characterization, and Skin Biodistribution Studies.

Pharmaceutics·2021

Related Experiment Video

Updated: Sep 1, 2025

Assay to Measure Nucleocytoplasmic Transport in Real Time within Motor Neuron-like NSC-34 Cells
08:53

Assay to Measure Nucleocytoplasmic Transport in Real Time within Motor Neuron-like NSC-34 Cells

Published on: May 16, 2017

8.8K

Inborn Errors of Nucleoside Transporter (NT)-Encoding Genes (SLC28 and SLC29).

Marçal Pastor-Anglada1,2,3, Aida Mata-Ventosa1,2,3, Sandra Pérez-Torras1,2,3

  • 1Departament de Bioquímica i Biomedicina Molecular, Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, 08028 Barcelona, Spain.

International Journal of Molecular Sciences
|August 12, 2022
PubMed
Summary

Genetic mutations in nucleoside and nucleobase transporters cause rare diseases. Understanding these transporters is key to understanding their associated clinical impacts and potential metabolic compensation mechanisms.

Keywords:
geneticsnucleosidesrare diseasestransporters

More Related Videos

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

33.9K
In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

13.8K

Related Experiment Videos

Last Updated: Sep 1, 2025

Assay to Measure Nucleocytoplasmic Transport in Real Time within Motor Neuron-like NSC-34 Cells
08:53

Assay to Measure Nucleocytoplasmic Transport in Real Time within Motor Neuron-like NSC-34 Cells

Published on: May 16, 2017

8.8K
Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

33.9K
In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

13.8K

Area of Science:

  • Biochemistry
  • Genetics
  • Cellular Biology

Background:

  • Nucleotide pool regulation is vital for cellular functions, relying on biosynthesis, salvage, and degradation.
  • While enzyme deficiencies in these pathways are linked to rare diseases, genetic impacts on nucleoside and nucleobase transporters are less understood.

Purpose of the Study:

  • To review current knowledge on genetic alterations affecting nucleoside and nucleobase transporters.
  • To elucidate the clinical and biochemical consequences of mutations in specific transporter genes.
  • To explore potential compensatory mechanisms in transporter deficiencies.

Main Methods:

  • Literature review of genetic alterations in nucleoside and nucleobase transporters.
  • Analysis of reported clinical manifestations and syndromes associated with transporter deficiencies.
  • Examination of physiological, molecular, and structural features of transporter proteins.

Main Results:

  • Mutations in SLC29A1, SLC29A3, and SLC28A1 affect ENT1, ENT3, and CNT1 transporters, respectively.
  • ENT1 mutations cause Augustine-null blood type and ectopic calcification.
  • ENT3 deficiency leads to histiocytosis-lymphoadenopathy plus syndrome; CNT1 deficiency causes uridine-cytidineuria.

Conclusions:

  • Deficiencies in ENT1, ENT3, and CNT1 transporters result in distinct rare diseases with varying clinical impacts.
  • Further research into transporter physiology and structure aids understanding of disease mechanisms.
  • These deficiencies may not severely disrupt nucleotide homeostasis but affect other biological processes.